Fixed vial sizes for controversial Alzheimer’s drug could waste $605 million in Medicare spending each year
Medicare could waste up to $605 million per year on the controversial Alzheimer’s drug aducanumab if it is eventually approved for widespread use because it is supplied in vials containing fixed doses that may not be appropriate for all patients–resulting…